Bambuterol

Bambuterol

Bambuterol
Systematic (IUPAC) name
(RS)-5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate)
Clinical data
AHFS/Drugs.com
Pregnancy
category
  • Unknown
Legal status
  • (Prescription only)
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 20%
Metabolism Hepatic, extensive
Further metabolized to terbutaline by plasma cholinesterase
Biological half-life 13 hours (bambuterol)
21 hours (terbutaline)
Excretion Renal
Identifiers
CAS Registry Number  Y
ATC code R03
PubChem CID:
IUPHAR/BPS
DrugBank  N
ChemSpider  Y
UNII  N
KEGG  Y
ChEBI  N
ChEMBL  Y
Chemical data
Formula C18H29N3O5
Molecular mass 367.44 g/mol
 N   

Bambuterol is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline. Commercially, the AstraZeneca pharmaceutical company produces and markets bambuterol as Bambec and Oxeol (INN).[1]

Contents

  • Indications 1
    • Contraindications 1.1
  • Adverse effects 2
  • Interactions 3
  • References 4

Indications

As other LABAs, bambuterol is used in the long-term management of persistent asthma.[1] It should not be used as a rescue medication for short-term relief of asthma symptoms.

Contraindications

Bambuterol is contraindicated in pregnancy and in people with seriously impaired liver function. It can be used by people with renal impairment, but dose adjustments are necessary.[1]

Adverse effects

The adverse effect profile of bambuterol is similar to that of salbutamol, and may include fatigue, nausea, palpitations, headache, dizziness and tremor.[1]

Interactions

Concomitant administration of bambuterol with corticosteroids, diuretics, and xanthine derivatives (such as theophylline) increases the risk of hypokalemia (decreased levels of potassium in the blood).[2]

Bambuterol acts as a cholinesterase inhibitor, and can prolong the duration of action of suxamethonium (succinylcholine) and other drugs whose breakdown in the body depends on cholinesterase function.[1] Butyrylcholinesterase activity returns to normal approximately two weeks after bambuterol is stopped.[3] It can also enhance the effects of non-depolarizing neuromuscular blockers, such as vecuronium bromide.[2]

References

  1. ^ a b c d e Sweetman, Sean C., ed. (2009). "Bronchodilators and Anti-asthma Drugs".  
  2. ^ a b Sweetman (2009), pp. 1132–33.
  3. ^ Sitar DS (October 1996). "Clinical pharmacokinetics of bambuterol". Clin Pharmacokinet 31 (4): 246–56.